Literature DB >> 6135707

Mechanisms of postprandial glucose counterregulation in man. Physiologic roles of glucagon and epinephrine vis-a-vis insulin in the prevention of hypoglycemia late after glucose ingestion.

T F Tse, W E Clutter, S D Shah, P E Cryer.   

Abstract

The transition from exogenous glucose delivery to endogenous glucose production late after glucose ingestion is not solely attributable to dissipation of insulin and, therefore, must also involve factors that actively raise the plasma glucose concentration--glucose counterregulatory factors. We have shown that the secretion of two of these, glucagon and epinephrine, is specific for glucose ingestion and temporally related to the glucose counterregulatory process. To determine the physiologic roles of glucagon and epinephrine in postprandial glucose counterregulation, we produced pharmacologic interventions that resulted in endogenous glucagon deficiency with and without exogenous glucagon replacement, adrenergic blockade, and adrenergic blockade coupled with glucagon deficiency starting 225 min after the ingestion of 75 g of glucose in normal subjects. Also, we assessed the effect of endogenous epinephrine deficiency alone and in combination with glucagon deficiency late after glucose ingestion in bilaterally adrenalectomized subjects. Glucagon deficiency resulted in nadir plasma glucose concentrations that were approximately 30% lower (P less than 0.01) than control values, but did not cause hypoglycemia late after glucose ingestion. This effect was prevented by glucagon replacement. Neither adrenergic blockade nor epinephrine deficiency alone impaired the glucose counterregulatory process. However, combined glucagon and epinephrine deficiencies resulted in a progressive fall in mean plasma glucose to a hypoglycemic level late after glucose ingestion; the final glucose concentration was 40% lower (P less than 0.02) than the control (epinephrine deficient) value in these patients, and was nearly 50% lower (P less than 0.001) than the control value and approximately 30% lower (P less than 0.05) than the glucagon-deficient value in normal subjects. We conclude (a) the transition from exogenous glucose delivery to endogenous glucose production late after glucose ingestion is the result of the coordinated diminution of insulin secretion and the resumption of glucagon secretion. (b) Epinephrine does not normally play a critical role in this process, but enhanced epinephrine secretion compensates largely and prevents hypoglycemia when glucagon secretion is deficient.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6135707      PMCID: PMC1129183          DOI: 10.1172/jci110967

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  23 in total

1.  Heterogeneity of plasma glucagon immunoreactivity in normal, depancreatized, and alloxan-diabetic dogs.

Authors:  I Valverde; R Dobbs; R H Unger
Journal:  Metabolism       Date:  1975-09       Impact factor: 8.694

2.  The role of the liver in glucagon metabolism.

Authors:  J B Jaspan; A H Huen; C G Morley; A R Moossa; A H Rubenstein
Journal:  J Clin Invest       Date:  1977-08       Impact factor: 14.808

3.  Hormonal mechanisms of recovery from insulin-induced hypoglycemia in man.

Authors:  J Gerich; J Davis; M Lorenzi; R Rizza; N Bohannon; J Karam; S Lewis; R Kaplan; T Schultz; P Cryer
Journal:  Am J Physiol       Date:  1979-04

4.  Concentrations of glucagon and the insulin:glucagon ratio in the portal and peripheral circulation.

Authors:  P Felig; R Gusberg; R Hendler; F E Gump; J M Kinney; P J Mulrow
Journal:  Proc Soc Exp Biol Med       Date:  1974-10

5.  Role of glucagon, catecholamines, and growth hormone in human glucose counterregulation. Effects of somatostatin and combined alpha- and beta-adrenergic blockade on plasma glucose recovery and glucose flux rates after insulin-induced hypoglycemia.

Authors:  R A Rizza; P E Cryer; J E Gerich
Journal:  J Clin Invest       Date:  1979-07       Impact factor: 14.808

6.  Pancreatic glucagon response to an ordinary meal.

Authors:  H Dencker; P Hedner; J Holst; K G Tranberg
Journal:  Scand J Gastroenterol       Date:  1975       Impact factor: 2.423

7.  Norepinephrine and epinephrine release and adrenergic mediation of smoking-associated hemodynamic and metabolic events.

Authors:  P E Cryer; M W Haymond; J V Santiago; S D Shah
Journal:  N Engl J Med       Date:  1976-09-09       Impact factor: 91.245

8.  Differential effects of epinephrine on glucose production and disposal in man.

Authors:  R Rizza; M Haymond; P Cryer; J Gerich
Journal:  Am J Physiol       Date:  1979-10

9.  Initial splanchnic extraction of ingested glucose in normal man.

Authors:  J Radziuk; T J McDonald; D Rubenstein; J Dupre
Journal:  Metabolism       Date:  1978-06       Impact factor: 8.694

10.  Effect of intermittent endogenous hyperglucagonemia on glucose homeostasis in normal and diabetic man.

Authors:  R Rizza; C Verdonk; J Miles; F J Service; J Gerich
Journal:  J Clin Invest       Date:  1979-06       Impact factor: 14.808

View more
  14 in total

1.  Divalent cation regulation of the surface orientation of platelet membrane glycoprotein IIb. Correlation with fibrinogen binding function and definition of a novel variant of Glanzmann's thrombasthenia.

Authors:  M H Ginsberg; A Lightsey; T J Kunicki; A Kaufmann; G Marguerie; E F Plow
Journal:  J Clin Invest       Date:  1986-10       Impact factor: 14.808

2.  Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms.

Authors:  N S Schwartz; W E Clutter; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1987-03       Impact factor: 14.808

3.  Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study.

Authors:  Morey W Haymond; Maria J Redondo; Siripoom McKay; Martin J Cummins; Brett Newswanger; John Kinzell; Steven Prestrelski
Journal:  Diabetes Care       Date:  2016-02-09       Impact factor: 19.112

4.  HIF2α Is an Essential Molecular Brake for Postprandial Hepatic Glucagon Response Independent of Insulin Signaling.

Authors:  Sadeesh K Ramakrishnan; Huabing Zhang; Shogo Takahashi; Brook Centofanti; Sarvesh Periyasamy; Kevin Weisz; Zheng Chen; Michael D Uhler; Liangyou Rui; Frank J Gonzalez; Yatrik M Shah
Journal:  Cell Metab       Date:  2016-02-04       Impact factor: 27.287

5.  Effect of ketone bodies on glucose production and utilization in the miniature pig.

Authors:  M J Müller; U Paschen; H J Seitz
Journal:  J Clin Invest       Date:  1984-07       Impact factor: 14.808

6.  Epinephrine supports the postabsorptive plasma glucose concentration and prevents hypoglycemia when glucagon secretion is deficient in man.

Authors:  S G Rosen; W E Clutter; M A Berk; S D Shah; P E Cryer
Journal:  J Clin Invest       Date:  1984-02       Impact factor: 14.808

7.  Glucoregulation during exercise: hypoglycemia is prevented by redundant glucoregulatory systems, sympathochromaffin activation, and changes in islet hormone secretion.

Authors:  D R Hoelzer; G P Dalsky; W E Clutter; S D Shah; J O Holloszy; P E Cryer
Journal:  J Clin Invest       Date:  1986-01       Impact factor: 14.808

8.  Postprandial hyperglycemia in patients with noninsulin-dependent diabetes mellitus. Role of hepatic and extrahepatic tissues.

Authors:  R G Firth; P M Bell; H M Marsh; I Hansen; R A Rizza
Journal:  J Clin Invest       Date:  1986-05       Impact factor: 14.808

9.  Mechanisms of glucagon secretion during insulin-induced hypoglycemia in man. Role of the beta cell and arterial hyperinsulinemia.

Authors:  G Bolli; P De Feo; G Perriello; S De Cosmo; P Compagnucci; F Santeusanio; P Brunetti; R H Unger
Journal:  J Clin Invest       Date:  1984-04       Impact factor: 14.808

10.  alpha2A-adrenoceptor antagonism increases insulin secretion and synergistically augments the insulinotropic effect of glibenclamide in mice.

Authors:  V Fagerholm; M Scheinin; M Haaparanta
Journal:  Br J Pharmacol       Date:  2008-05-19       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.